Printer Friendly

SUMMIT RECEIVES FDA APPROVAL TO CONDUCT CLINICAL TRIALS FOR TOPICAL PHARMACEUTICALS

 WALTHAM, Mass., Jan. 12 /PRNewswire/ -- Summit Technology, Inc. (NASDAQ: BEAM) announced today that the FDA has granted the company an expansion of it Photorefractive Keratectomy (PRK) clinical investigation to permit the treatment of an additional 200 patients. This expansion allows Summit and Allergan, Inc. (NYSE: AGN) to conduct joint clinical trials of certain topical pharmaceuticals for post-operative use following PRK.
 If the clinical studies are successful and the FDA gives marketing approval for this indication, these Allergan pharmaceuticals would be distributed by Summit along with Summit's other disposable products.
 PRK is an outpatient procedure which is used to treat common refractive disorders such as nearsightedness, farsightedness and astigmatism. In as short a time as 10 seconds, the laser gently reshapes the cornea, obviating in most cases the reliance on eyeglasses or contact lenses.
 Summit Technology, Inc. is a worldwide leader in the development, manufacture and sale of ophthalmic laser systems designed to correct common refractive vision disorders such as nearsightedness, farsightedness and astigmatism.
 -0- 1/12/94
 /CONTACT: Paula Rainville, investor relations of Summit Technology, 617-890-1234/
 (BEAM AGN)


CO: Summit Technology, Inc.; Allergan, Inc. ST: Massachusetts IN: MTC SU:

CM -- NE004 -- 1268 01/12/94 08:07 EST
COPYRIGHT 1994 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1994 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jan 12, 1994
Words:198
Previous Article:SCIMED RECEIVES FDA APPROVAL TO MARKET DISPATCH CORONARY INFUSION CATHETER
Next Article:NEW GALLUP SURVEY DOCUMENTS DEVASTATING EFFECTS OF MIGRAINE ON SUFFERERS' LIVES
Topics:

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters